SOM230

Phase 2Small molecule

Novartis

SOM230 is one of 95 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Cluster HeadacheActive, not recruiting

Dumping SyndromeActive, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Cluster HeadachePhase 2

Active, not recruiting

Dumping SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

SOM230

Novartis

Phase 2

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Ifex

BBaxter Healthcare Corporation

Preclinical

—9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cushing's Disease1 trial

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

Completed· Novartis logo

Novartis·Phase 2·NCT00088608·26 enrolled

Dumping Syndrome1 trial

Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome

Completed· Novartis logo

Novartis·Phase 2·NCT01637272·43 enrolled

Neuroendocrine Tumors1 trial

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Completed·—·Phase 1·NCT00804336·22 enrolled

Metastatic1 trial

Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Completed· Novartis logo

Novartis·Phase 1·NCT01590199·18 enrolled

Cluster headache1 trial

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

Terminated· Novartis logo

Novartis·Phase 2·NCT02619617·28 enrolled

4 more indications

Prostate Cancer1 trial

Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT01646684·9 enrolled

Hepatocellular Carcinoma1 trial

Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma

Completed·LLynn Feun·Phase 2·NCT01639352·20 enrolled

Renal Impairment1 trial

A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 1·NCT01578928·50 enrolled

Multiple Myeloma1 trial

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

Withdrawn·UUniversity of Pittsburgh·Phase 2·NCT01329289

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for SOM230. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SOM230 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SOM230. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

SOM230

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cushing's Disease1 trial

Dumping Syndrome1 trial

Neuroendocrine Tumors1 trial

Metastatic1 trial

Cluster headache1 trial

Prostate Cancer1 trial

Hepatocellular Carcinoma1 trial

Renal Impairment1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News